Clinical Trial Search

Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline to Last Observation Carried Forward (LOCF) — -2.8; -3.1; -2.1; -2.6 scores on a scale — p=0.385

Primary: Objective Response Rate (ORR) — 14.2 percentage of participants

Primary: Aggregated Pathology Score — 7.88; 8.15 Score on a scale

Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) by Dose — 6; 91; 2; 64 Participants

Primary: Number of Participants With Overall Clinical Benefit (OCB), Defined as the Sum of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) Divided by the…

Primary: Measurable Silibinin Tissue Levels — 3 Participants

Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022

Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…

Primary: Response to Induction Chemotherapy — 74; 11 Participants

Primary: Number of Drinks Per Week — 13.8; 12.0 standard alcohol drinks per week — p=0.82

Primary: Mediastinal Nodal Clearance Rate — 27 participants

Primary: Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation — 48; 30 participants

Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants

Primary: Number Meeting Success Criterion — 10; 5; 0 participants meeting success criterion — p=>0.05

Primary: Treatment Effectiveness Score — 16.1; 10.6 urine drug screens